HAMI 3379 is a selective CysLT2 receptor antagonist. HAMI 3379 protects against acute brain injury after focal cerebral ischemia in rats. HAMI 3379 attenuates ischemia-like neuronal injury by inhibiting microglial activation. HAMI 3379 effectively blocked CysLT2R-mediated microglial activation, thereby indirectly attenuating ischemic neuronal injury. Therefore, CysLT2R antagonists may represent a new type of therapeutic agent in the treatment of ischemic stroke. References: Xu DM, Zhang XY, Wang XR, Chen L, Zhang LH, Shi QJ, Fang SH, Lu YB, Zhang WP, Wei EQ. [Antioxidative effects of cysteinyl leukotriene receptor antagonists montelukast and HAMI 3379 on ischemic injury in rat cortical neurons in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):257-64. Chinese. PubMed PMID: 24998647.

纯度：≥98%

CAS：712313-35-4